Related Experiment Video

Updated: May 15, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

PAK1 mediates resistance to PI3K inhibition in lymphomas

Katherine Walsh1, Matthew S McKinney, Cassandra Love

  • 1Duke Institute for Genome Sciences and Policy and Department of Medicine, Duke Cancer Institute, Duke University Medical Center, Duke University, Durham, North Carolina, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|January 10, 2013
PubMed
Abstract

Insights

Phosphoinositide 3-kinase (PI3K) inhibition shows broad effectiveness in treating lymphomas. Targeting the PAK1 gene can overcome resistance to PI3K inhibitors, offering a new therapeutic strategy for lymphoma patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The phosphoinositide 3-kinase (PI3K) pathway is implicated in various cancers.
  • The therapeutic potential of PI3K inhibition in lymphomas requires further elucidation.

Purpose of the Study:

  • To investigate the efficacy of PI3K inhibition in a diverse range of B-cell lymphomas.
  • To identify molecular mechanisms governing response and resistance to PI3K inhibitors.

Main Methods:

  • Screened three small molecule inhibitors (BKM120, BEZ235, BGT226) across 60 lymphoma cell lines.
  • Utilized gene expression profiling to analyze drug response.
  • Employed RNA-interference to assess the role of PAK1 gene.

Main Results:

  • Elevated PAK1 gene expression correlated significantly with resistance to PI3K inhibitors.
  • PAK1 gene knockdown markedly enhanced sensitivity to PI3K inhibition.
  • Combined inhibition of PI3K and PAK1 demonstrated synergistic effects.

Conclusions:

  • PI3K inhibition is a broadly effective therapeutic strategy for lymphomas.
  • PAK1 acts as a critical regulator of resistance to PI3K-targeted therapies in lymphomas.

More Related Videos

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...